Viewing nowCombinationPosidime Sustained Release Tablet 10/500 mg
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.

MFDS item code 202300274 · Approved 2023.01.17 · Insurance code 643705400
Improvement of glycemic control in adults with type 2 diabetes
This medication is used in combination with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes by combining dapagliflozin and metformin. Particularly, in patients whose blood sugar is not sufficiently controlled and have cardiovascular disease or risk factors, careful management of the impact on cardiovascular events should be performed in accordance with expert guidance. Overall, it helps in effective blood sugar management in type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy alone: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switched from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is used to help control blood sugar in treating diabetes. It can rarely cause a dangerous condition called lactic acidosis, so patients with poor kidney function or severe infections, dehydration, etc. should not use it. Moreover, caution is needed when used in conjunction with insulin or other hypoglycemic agents, as this may lead to symptoms of hypoglycemia. Patients with moderate to severe renal impairment, those scheduled for acute illness or surgery, hepatically impaired patients, pregnant women, or nursing mothers should not use this medication. This medication should be carefully administered to patients with reduced fluid volume or risk of hypotension, and fluid status and kidney function must be evaluated prior to administration. During use, symptoms of hypoglycemia, lactic acidosis, signs of infection, etc. should be closely observed, and if abnormal symptoms occur, immediate consultation with healthcare professionals is required. This medication may increase the risk of genital and urinary infections, necessitating appropriate treatment if infection symptoms appear. Vitamin B12 levels may decrease, so regular blood tests may be needed for long-term use. Alcohol may increase the risk of side effects from this medication; therefore, excessive drinking should be avoided during administration. This medication may affect certain test results, and when assessing blood sugar control, other tests should be used. Elderly patients or those with impaired kidney function should have dosage adjustments and kidney function monitoring prioritized. Pregnant women and nursing mothers should not use this medication and should discontinue use immediately upon confirmation of pregnancy. In case of overdose, immediate medical attention is required, and dialysis may be beneficial in cases of poor kidney function. This medication does not exert significant effects on driving or operating machinery; however, caution is advised as dizziness and other symptoms may occur. Store out of reach of children and keep in the original container to prevent safety accidents and degradation of quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, and it is best kept at room temperature between 1 to 30 degrees Celsius. Maintaining this condition helps to retain the effectiveness of the medication for a longer time.
Pink rectangular sustained release film-coated tablet
30 tablets/box[(6 tablets/PTP)X5], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
YouYoung Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Yuyoung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.